Literature DB >> 36072559

Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in silico and in vitro studies.

Homa Fatma1, Santosh Kumar Maurya1, Akhilesh Kumar Maurya2, Nidhi Mishra2, Hifzur R Siddique1.   

Abstract

Prostate cancer (CaP) is one of the most frequent malignancies amongst men. Enzalutamide is the second-generation potent androgen receptor (AR) antagonist used against metastatic and non-metastatic CaP. Unfortunately, the development of chemoresistance in cancer cells reduces the effectiveness of Enzalutamide. Lupeol is a pentacyclic triterpene found in different fruits, vegetables, and medicinal plants and possesses anti-inflammatory and anti-cancer properties. Here, we report in silico and in vitro studies of Lupeol and Enzalutamide against the β-CATENIN, c-FLIPL, and c-MYC, which play a significant role in chemoresistance. We observed that Lupeol significantly inhibits the cell growth of chemoresistant Du145 cells and cancer stem cells (CSCs) either alone or in combination with Enzalutamide. Lupeol and Enzalutamide were also found to dock with β-CATENIN, c-FLIPL, and c-MYC. The following MD simulation data showed both compounds exerting structural changes in these proteins. Finally, they significantly inhibit the transcriptional activity of all these genes, as observed by luciferase assay. Thus, we infer that Lupeol chemosensitizes the CaP cells for Enzalutamide-resistant CaP cells.
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Entities:  

Keywords:  Cancer stem cells; Chemoresistance; Chemosentization; Enzalutamide; Lupeol; Prostate cancer

Year:  2022        PMID: 36072559      PMCID: PMC9441409          DOI: 10.1007/s40203-022-00131-3

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  29 in total

1.  Molecular dynamics simulations of PNA-PNA and PNA-DNA duplexes by the use of new parameters implemented in the GROMACS package: a conformational and dynamics study.

Authors:  Ida Autiero; Michele Saviano; Emma Langella
Journal:  Phys Chem Chem Phys       Date:  2014-02-07       Impact factor: 3.676

2.  SwissParam: a fast force field generation tool for small organic molecules.

Authors:  Vincent Zoete; Michel A Cuendet; Aurélien Grosdidier; Olivier Michielin
Journal:  J Comput Chem       Date:  2011-05-03       Impact factor: 3.376

3.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

Review 4.  Molecular dynamics simulations and novel drug discovery.

Authors:  Xuewei Liu; Danfeng Shi; Shuangyan Zhou; Hongli Liu; Huanxiang Liu; Xiaojun Yao
Journal:  Expert Opin Drug Discov       Date:  2017-11-15       Impact factor: 6.098

5.  Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing.

Authors:  Rohan Patil; Suranjana Das; Ashley Stanley; Lumbani Yadav; Akulapalli Sudhakar; Ashok K Varma
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

6.  Chemosensitization of Therapy Resistant Tumors: Targeting Multiple Cell Signaling Pathways by Lupeol, A Pentacyclic Triterpene.

Authors:  Santosh K Maurya; G G H A Shadab; Hifzur R Siddique
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 7.  Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene.

Authors:  Mohammad Saleem
Journal:  Cancer Lett       Date:  2009-05-22       Impact factor: 8.679

8.  A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.

Authors:  Alina Castell; Qinzi Yan; Karin Fawkner; Per Hydbring; Fan Zhang; Vasiliki Verschut; Marcela Franco; Siti Mariam Zakaria; Wesam Bazzar; Jacob Goodwin; Giovanna Zinzalla; Lars-Gunnar Larsson
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

9.  A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.

Authors:  Shanshan Bai; Subing Cao; Lianjin Jin; Margaret Kobelski; Blake Schouest; Xiaojie Wang; Nathan Ungerleider; Melody Baddoo; Wensheng Zhang; Eva Corey; Robert L Vessella; Xuesen Dong; Kun Zhang; Xianghui Yu; Erik K Flemington; Yan Dong
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

Review 10.  B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer.

Authors:  Qipeng Liu; Qiaqia Li; Sen Zhu; Yang Yi; Qi Cao
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.